NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT

CompletedNA

Sponsor: Istituti Clinici Scientifici Maugeri SpA

Conditions: Multiple Sclerosis

Interventions: 18F-florbetaben PET/CT

Countries: Italy

The goal of this clinical trial study is to evaluate the presence of relationships between PET and MRI images indicative of chronic inflammatory activity (smoldering plaques), apparent absence of inflammatory activity (silent plaques without microglial rim), or indicative of more recent inflammatory activity, in contrast-enhanced areas or in T2/Flair-positive areas of not distant onset in patients diagnosed with progressive (secondary or primary) stage multiple sclerosis and in patients in relapse and remission. Laboratory analysis of serum markers will be performed: neuronal and glial cytoskeletal proteins (e.g., Nf-L, pN-FH, GFAP), and the levels of neurotrophic factors (e.g., BDNF, GDNF) and cytokines (e.g., TNFα, IL-6, IL-1β, interferon) will be evaluated.

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* progressive stage of multiple sclerosis (both secondary and primary, SMP)
* patients in relapsing-remitting multiple sclerosis (RRMS)

Exclusion Criteria:

* a disability greater than 7
* patients with a cognitive impairment interfering with full study participation (Minimental score less than 24)
* patients with internal medical problems that in the opinion of the investigator may interfere with full participation and collaboration
* inability to undergo MRI or PET examinations
* ongoing pregnancy and lactation

Locations (1)

Pavia, PV, Italy